MARKET

CLBS

CLBS

Caladrius
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.220
0.000
0.00%
After Hours: 1.220 0 0.00% 17:47 09/24 EDT
OPEN
1.220
PREV CLOSE
1.220
HIGH
1.230
LOW
1.210
VOLUME
180.76K
TURNOVER
--
52 WEEK HIGH
4.890
52 WEEK LOW
1.150
MARKET CAP
72.61M
P/E (TTM)
-1.4301
1D
5D
1M
3M
1Y
5Y
Caladrius Biosciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
Caladrius Biosciences, Inc. (Nasdaq: CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that David J. Mazzo, PhD, President and CE...
GlobeNewswire · 09/08 12:00
BRIEF-Caladrius Biosciences Appoints Of Kristen Buck As Chief Medical Officer
reuters.com · 09/01 12:54
The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17)
Benzinga · 08/18 11:37
The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 16)
Benzinga · 08/17 12:28
BRIEF-Caladrius Biosciences Reports Second Quarter 2021 Financial Results
reuters.com · 08/05 21:48
Caladrius Biosciences, Inc. (CLBS) Reports Q2 Loss, Misses Revenue Estimates
Zacks.com · 08/05 21:25
Caladrius Biosciences Reports Second Quarter 2021 Financial Results and Provides Business Update
Caladrius Biosciences, Inc. (Nasdaq: CLBS) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, provides a corporate update and reports financial results ...
GlobeNewswire · 08/05 21:16
Caladrius Biosciences EPS beats by $0.04
Caladrius Biosciences (NASDAQ:CLBS): Q2 GAAP EPS of -$0.10 beats by $0.04. Revenue of $43.29M (+138.1% Y/Y) Press Release
Seekingalpha · 08/05 20:12
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CLBS. Analyze the recent business situations of Caladrius through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CLBS stock price target is 10.00 with a high estimate of 10.00 and a low estimate of 10.00.
EPS
Institutional Holdings
Institutions: 35
Institutional Holdings: 6.34M
% Owned: 10.66%
Shares Outstanding: 59.52M
TypeInstitutionsShares
Increased
6
194.17K
New
3
276.24K
Decreased
7
237.29K
Sold Out
7
638.85K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.13%
Pharmaceuticals & Medical Research
-1.02%
Key Executives
Non-Executive Chairman/Independent Director
Gregory Brown
President/Chief Executive Officer/Director
David Mazzo
Senior Vice President/General Counsel/Secretary
Todd Girolamo
Vice President
William Sietsema
Independent Director
Michael Davidson
Independent Director
Steven Klosk
Independent Director
Steven Myers
Independent Director
Cynthia Schwalm
Independent Director
Peter Traber
Independent Director
Anne Whitaker
No Data
  • All
  • Financials
  • Insiders
More
About CLBS
Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of cellular therapies. The Company is developing therapeutics based on the characteristics of naturally occurring CD34+ cells. Its product candidates include CLBS16, the subject of both a positive Phase IIa study and Phase IIb (FREEDOM) study in the United States for the treatment of coronary microvascular dysfunction (CMD); HONEDRA (CLBS12), recipient of SAKIGAKE designation in Japan for the treatment of critical limb ischemia (CLI); CLBS201, designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for patients with pre-dialysis chronic kidney disease (CKD), and OLOGO (CLBS14), which reduces mortality, improves angina and increases exercise capacity in patients with otherwise untreatable angina, the product received Regenerative Medicine Advanced Therapy (RMAT) designation from the United States Food and Drug Administration (FDA).

Webull offers kinds of Caladrius Biosciences Inc stock information, including NASDAQ:CLBS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLBS stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CLBS stock methods without spending real money on the virtual paper trading platform.